Enhanced pharmacokinetic and therapeutic of GSH-responsive mPEG-b-P(HPMA)-SGI1776 conjugate for osteosarcoma
The conjugate is more likely to induce apoptosis and can be blocked 143b cells in the S cycle phase. The maximum plasma concentration of the conjugate is attained 0.52 ± 0.092 μg/mL at 4 ± 0 h after the oral administration. The conjugate exhibits better lysosomal escape ability, biocompatibility.
Authors
- Zhenghua Zhang (ORCID: https://orcid.org/0000-0003-0880-0240)
- Rui Wang (ORCID: https://orcid.org/0000-0003-3735-6177)
- Xinyi Shi (ORCID: https://orcid.org/0000-0002-4427-2281)
- Weibing Xu (ORCID: https://orcid.org/0000-0002-1348-9314)
- Xin-He Shi
- Zhe Geng
- Zixuan Wang (ORCID: https://orcid.org/0009-0009-9134-4952)
Institutions
- Gansu Agricultural University (CN)
- Lanzhou University of Technology (CN)
- Lanzhou University Second Hospital (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3389/fphar.2025.1676770
- Primary Topic
- Cancer Mechanisms and Therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Gansu Province